Competitive landscape, page-244

There are numerous R&D companies working on T- cell therapies that are showing excellent results compared to the SOC.
They target specific cancers or in some circumstances several cancer types and are expensive to produce.
This is where Imugene are on a different level with products that will be not only cheaper to produce, provide fewer side effects, easier to administer, can be used in combination with existing theropies and if CF33 continues to produce & provide undeniable scientific results, will blow the competition out of the water if / when it becomes available as a new standard of care (SOC).
Quite amazing really when you think about it.
In terms of the share price doing a Bradbury - really looking forward to the day it re-gets momentum then - whooshka.